SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $750,409,524 |
| Positions | 11 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| NEWAMSTERDAM PHARMA COMPANY | NAMS | ORDINARY SHARES | $287,738,063 | 8,490,353 |
| MAPLIGHT THERAPEUTICS INC | MPLT | COM | $115,634,176 | 3,226,400 |
| DYNE THERAPEUTICS INC | DYN | COM | $85,469,766 | 3,848,256 |
| VOR BIOPHARMA INC | VOR | COM NEW | $75,800,487 | 4,117,354 |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $63,490,410 | 2,441,000 |
| REPLIMUNE GROUP INC | REPL | COM | $31,088,634 | 2,808,368 |
| CRESCENT BIOPHARMA INC. | CBIO | COM | $30,201,336 | 1,677,852 |
| AURA BIOSCIENCES INC | AURA | COM | $28,781,803 | 4,053,775 |
| ENGENE HOLDINGS INC | ENGN | COM | $16,664,330 | 9,632,561 |
| BICYCLE THERAPEUTICS PLC | BCYC | SPONSORED ADS | $14,706,143 | 3,468,430 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.